MiR-184-based supplementary therapeutics and mTOR pathway inhibitor, like rapamycin, can inhibit RPE dedifferentiation in dry AMD and may become prospective options for treating retinal degenerative diseases. This evidence concerns the gene MTOR and dry age related macular degeneration.